Epithelial ovarian cancer (EOC) has one of the highest deaths to incidence ratios.
ABSTRACT: Epithelial ovarian cancer (EOC) has one of the highest deaths to incidence ratios.
High grade serous ovarian carcinoma (HGSOC) is the most common and deadliest EOC histotype because of the lack of secondary therapeutic options following debulking surgery and platinum/taxane-based chemotherapies. For recurrent chemosensitive HGSOC, poly(ADP)ribose polymerase inhibitors (PARPi; olaparib, rucaparib, or niraparib) represent an emerging treatment strategy. While PARPi are most effective in homologous recombination DNA repairdeficient (HRD) HGSOCs, more recent studies have observed a significant clinical benefit in non-HRD HGSOCs. However, all HGSOC patients are likely to acquire resistance to PARPi. Therefore, there is an urgent clinical need to better understand PARPi resistance, and to introduce novel combinatorial therapies to overcome PARPi resistance and extend HGSOC disease-free intervals. Utilizing a two BRCA2-mutated and one BRCA-wildtype HGSOC cell lines that are olaparib sensitive, we established resistant cells. Transcriptome analysis of the matched olaparib-sensitive versus resistant cells did not detect BRCA2 reversion mutations, but revealed activation of Wnt/TCF signaling pathway, as TCF transcriptional activity was significantly increased in PARPi-resistant cells. In parallel, forced activation of Wnt signaling in PARPi-sensitive cells via WNT3A stimulation reduced response to PARPi. In a recurrent-HGSOC PARPi insensitive patient-derived xenograft model there was an increase in a Wnt/TCF transcriptional target. PARPi resistant cells were sensitive to inhibition of Wnt signaling using the FDA-approved compound, pyrvinium pamoate, which has been shown to inhibit Wnt signaling. We observed that combining pyrvinium pamoate with olaparib resulted in a significant decrease in tumor burden and number of tumor nodules. This study demonstrates that Wnt signaling can mediate PARPi resistance in HGSOC and provides a clinical rationale for combining PARPi and Wnt inhibitors.
INTRODUCTION:
Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy and has one of the highest deaths to incidence ratios (63 deaths:100 cases) (1) . The most common EOC histotype is high grade serous ovarian carcinoma (HGSOC) and over 85% of HGSOC are diagnosed at late stages (III/IV) (1) . About 80% of all HGSOC patients respond to first-line therapy, which includes surgical debulking and platinum/taxane-based chemotherapies.
However, HGSOC recurs in a majority of patients, and patients are subsequently treated with additional chemotherapeutic regimens (2) . As tumors acquire chemoresistance, disease-free intervals are shortened with each subsequent recurrence, which makes identifying effective and novel therapeutic strategies for recurrent HGSOC an urgent clinical need.
The Cancer Genome Atlas revealed approximately 50% of all HGSOC tumors have mutations or deficiencies in the homologous recombination (HR) DNA repair pathway (3) . For example, mutations and epigenetic silencing of BRCA1/2 are detected in 30% of HGSOC cases. HR-deficient cancers can be targeted in a synthetic lethal fashion using poly(ADP)-ribose polymerase (PARP) inhibitors (2, (4) (5) (6) . There are currently three PARP inhibitors (PARPi; olaparib, rucaparib, and niraparib) that are FDA-approved for the treatment of recurrent HGSOC. Patients with HR-deficient HGSOC tumors treated with PARPi have a significant clinical benefit but recent clinical trials have observed a clinical benefit in patients without measurable HR-deficiency (7, 8) . Nevertheless, in a similar fashion as first-line chemotherapies, PARPi treated patients will likely recur with resistant disease.
Tumorigenesis and chemoresistance in numerous cancer types, including ovarian cancer can be attributed to Wnt signaling. Canonical Wnt signaling is mediated through ligand (i.e. WNT3A) stimulation of frizzled (FZD) and lipoprotein receptor-related protein (LRP) receptors. WNT-receptor interactions promote sequestration of the β-catenin degradation complex and accumulation and nuclear localization of β -catenin. Increased β-catenin leads to its interaction with T-cell factor (TCF) and lymphoid enhancer factor (LEF) transcriptional activators and ultimately upregulation of TCF/LEF target genes (e.g. FOSL1). Previously, we established in HGSOC cell lines β-catenin-dependent TCF transcriptional activation is antagonized by non-canonical Wnt (β-catenin-independent) signaling, and in HGSOC primary tumor the attenuation of non-canonical Wnt signaling was associated with worse overall survival (9) . The observed overall survival was potentially due to the decreased time to chemoresistance. Hyperactivation of Wnt signaling has been attributed to chemotherapeutic resistance in a variety of epithelial-derived cancers including, ovarian, breast, and bladder (10) (11) (12) . Based on these observations, we investigated how aberrant activation of canonical βcatenin-dependent Wnt signaling regulates PARPi response and/or resistance.
In this study, we examined HGSOC models of acquired PARPi resistance. We observed in these models that hyperactivation of Wnt signaling pathway was necessary and sufficient for PARPi resistance. In two PARPi-resistant HGSOC cell lines we observed an increase in TCF transcriptional activity compared to parental cells. We screened a panel of Wnt signaling inhibitors and observed an FDA-approved compound (pyrvinium pamoate) induced cell death in PARPi-resistant cells at nanomolar concentrations. PARPi resistant cells had increased DNA repair capacity by both non-homologous end-joining (NHEJ) and HR, independent of BRCA2 reversion mutations. Pyrvinium pamoate effectively inhibited both NHEJ and HR-mediated repair in PARPi-resistant cells, and synergized with olaparib to induce apoptosis. In an ex vivo culture of a primary HGSOC tumor PARPi and pyrvinium pamoate reduced proliferation.
Utilizing a HGSOC cell line xenograft mouse model we demonstrated that combining olaparib with pyrvinium pamoate significantly inhibited the rate of tumor growth, disseminations and overall tumor burden in vivo.
RESULTS:
PARPi are most effective in homologous recombination deficient (HRD) tumors, however PARPi do convey a significant clinical benefit in most HGSOC patients (7, 8) . Acquired PARPi resistance needs to be examined to better understand mechanisms of action. Therefore, we established a panel of olaparib resistant HGSOC cell lines (PEO1-olaparib resistant, PEO1-OR;
OVCAR10-olaparib resistant, OVCAR10-OR, and OVSAHO-olaparib resistant, OVSAHO-OR) through step-wise dose escalation of olaparib. Olaparib resistance was confirmed with a dose response colony formation assay ( Fig. 1A and Sup. Fig. 1A ). In PEO1-OR cells we isolated four clonal populations and confirmed >25-fold increase in half maximal inhibitory concentrations in all four PEO1-OR clones ( Fig. 1B) . BRCA reversion mutations are a published mechanism of PARPi resistance (13) , using a N-terminal BRCA2 antibody we confirmed that BRCA2 protein expression was not restored in PEO1-OR clonal populations ( Fig. 1C ), suggesting an alternative mechanism of acquired olaparib resistance. Transcriptome analysis (RNA-sequencing; RNAseq) of the PEO1-OR clones was performed to identify differentially regulated gene expression and pathways compared to olaparib-sensitive PEO1. Principal component analysis and hierarchical clustering of sequencing showed that the sensitive and resistant cells clustered together (Sup. Fig 1B-C) . Although the PEO1-OR clones were independently isolated their transcriptome profiles were similar. Comparing sensitive cells to the four PEO1-OR clones there were 1,819 genes that were differentially regulated (FDR<15%, p<0.00001; Sup. Table 1 ). Gene Set Enrichment Analysis, pathway enrichment (KEGG) and transcription factor analysis (14, 15) of differentially expressed genes was performed to identify putative pathways mediating olaparib resistance. We identified that a majority of differentially expressed genes are regulated by TCF3 and LEF1 transcription factor ( Table 1) . KEGG pathway analysis revealed several highly enriched pathways including, MAPK signaling, focal adhesion, and Wnt signaling ( Table 2) .
Enrichment of TCF3/LEF1 and Wnt signaling is consistent with activation of canonical, βcatenin-dependent Wnt signaling in PEO1-OR clones. To confirm this, we examined TCF mediated transcriptional activation through a classic TCF reporter assay (TOP/FOP-FLASH), and observed a significant increase in TOP-FLASH activity in PEO1-OR and OVCAR10-OR cells versus the parental cells ( Fig. 1D and Sup. Fig. 1D ). OVSAHO-OR did not demonstrate a significant increase in TCF transcriptional activity (Sup. Fig. 1D ). In PEO1-OR we validated several genes identified by RNA-Seq that are associated with either activation (FOSL1, CCND1, WNT3A) or inhibition (WNT5A, WNT7B, SFRP1) of canonical Wnt signaling. We confirmed that Wnt signaling activators are upregulated and Wnt signaling inhibitors are repressed in PEO1-OR cell (Fig. 1E) . Notably, we observed a significant increase in WNT3A, a potent driver of canonical Wnt signaling. These data confirm the Wnt pathway is activated in olaparib resistant cells therefore we more closely examined the role of Wnt signaling in olaparib resistance.
PARPi resistant cells have increased Wnt signaling, therefore we wanted to know if Wnt hyperactivation was sufficient to drive PARPi resistance. To examine the impact on increased Wnt/TCF activation on olaparib response, the open-reading frame of a Wnt ligand (WNT3A) was transduced into olaparib-sensitive PEO1 cells. WNT3A expression was confirmed to be significantly upregulated through quantitative PCR (qPCR) and immunoblot ( Fig. 2A-B ). In PEO1-WNT3A, TCF transcriptional activity was significantly increased (Fig. 2C ), and canonical Wnt target genes (CCND1 and FOSL1) were upregulated following WNT3A overexpression ( Fig. 2D ). Next, olaparib sensitivity was assessed in PEO1-WNT3A via dose response colony formation. The overexpression of WNT3A promoted olaparib insensitivity ( Fig. 2E-F) . The Wntdependent decrease in olaparib sensitivity suggests that increased Wnt signaling contributes to PARPi resistance.
Since Wnt signaling was activated in olaparib-resistant HGSOC cells, and Wnt ligand over-expression was sufficient to reduce HGSOC cell sensitivity to olaparib, we examined the impact of pharmacologic inhibition of Wnt signaling when combined with olaparib. We blocked Wnt signaling by targeting distinct components of Wnt signaling, using a porcupine inhibitor (WNT-C59) to block Wnt ligand secretion, and two β-catenin inhibitors (PRI724 and Pyrvinium pamoate). PRI724 blocks β-catenin transcriptional activation by steric inhibiton of β-catenin and one if its co-activator's CBP (CREB binding protein). Pyrvinium pamoate (Pyr. Pam.) promotes β-catenin downregulation by activating the β-catenin degradation complex in a casein kinase 1dependent fashion (16) . WNT-C59 did not reduce PEO1 cell viability at the highest concentration tested (50µM) (Fig. 3A) . A secondary cell line, OVSAHO, was also utilized to determine the impact of Wnt inhibitor on HGSOC viability (Sup. Fig. 2A ). Pyrvinium pamoate (Pyr. Pam.) significantly inhibited cellular viability in both PEO1 (IC50=370.2nM) and OVSAHO (IC50=733.2nM). Notably, the PEO1-OR cells were significantly more sensitive to Pyr. Pam. compared to PEO1 (IC50=169.5nM versus IC50= 315nM, p<0.0001) ( Fig. 3B ). OVSAHO-OR cells also were more sensitive to Pyr. Pam. (Sup. Fig. 2B ) even in the absence of a significant increase in TCF activity (Sup. Fig. 1D ). Taken together these data suggests an increased dependence on Wnt/β-catenin signaling in olaparib resistant cells.
Pyr. Pam. is an FDA approved anthelminthic and inhibits Wnt signaling through activation of casein kinase 1 and stabilization of the β-catenin degradation complex. In vitro Pyr.
Pam. has been reported to inhibit colorectal, ovarian and aggressive breast cancers (17) (18) (19) .
We confirmed that Pyr. Pam. significantly reduced TCF transcriptional activity ( We next wanted to examine the mechanism of Wnt signaling mediated PARPi insensitivity. PARPi resistance independent of a BRCA-reversion mutation has been attributed to the restoration of DNA replication fork stability (20, 21) and/or increased DNA repair capacity.
Given ectopic expression of WNT3A resulted in decreased olaparib sensitivity and the potential of other confounding factors in PEO1-OR cells, we examined replication fork stability following WNT3A overexpression in the sensitive PEO1 cells. PEO1 and PEO1-WNT3A cells were pulsed with 2'-deoxy-5-iodouridine (IdU), treated with hydroxyurea (HU) to promote replication fork stalling, washed, and pulsed with 5-chloro-2'-deoxyuridine (CIdU). To assess replication fork degradation while excluding premature replication termination events, lengths of IdU tracks occurring adjacent to CldU tracks were measured. Although significant, WNT3A overexpression only marginally rescued HU-induced replication fork (RF) degradation (9.21 vs. 10.43 microns for PEO1 and PEO1-WNT3A, respectively, Sup. Fig 3A) . We therefore wanted to examine DNA repair capacity through functional repair assays.
We next evaluated DNA damage response by examining γH2Ax resolution and by utilizing two-plasmid functional assays. In a similar fashion as previously demonstrated (22) we utilized a marker of DNA damage (Serine 139 phosphorylated histone H2x, γH2Ax) and examined the rate of γH2Ax resolution as a DNA repair read-out. PEO1 sensitive and PEO1-OR cells were irradiated (5Gy) and γH2Ax was examined. Over an 8 hour time course PEO1-OR cells resolved γH2Ax 2.5X faster than PEO1 sensitive cells ( Fig. 4A-B) . We subsequently employed a functional two-plasmid DNA repair system to assess specific DNA repair pathways, HR, distal NHEJ and microhomology NHEJ (mh-NHEJ). Briefly, a unique restriction enzyme, I-SceI introduces DNA double strand breaks in a unique GFP-mutated plasmid and DNA repair by the specific pathway leads to the restoration of a GFP open-reading frame (23). To limit heterogeneity, within the assay PEO1-OR clonal populations were analyzed for the three different DNA repair pathways. Cells were incubated for 72hrs after transfection with I-SceI and using flow cytometry the percentage of GFP-positive cells was measured. Only one of the four PEO1-OR clones had a significant increase in mh-NHEJ-mediated repair compared to the sensitive control (Sup. Fig. 3B ). In contrast, all four PEO1-OR clones had a significant increase in distal-NHEJ ( Fig. 4C-D) and three of the four PEO1-OR clones had a significant increase in HR-mediated repair compared to the sensitive cells ( Fig. 4E ). Both distal-NHEJ and HRmediated DNA repair were significantly inhibited following Pyr. Pam. treatment ( Fig. 4F-G) . In PEO1-OR, DNA repair activity was abrogated by β-catenin inhibition suggesting a Wntdependent regulatory role in conveying increased DNA repair and PARPi resistance.
PARPi were initially developed to exploit HR-deficient tumors and restoration of HR decreases PARPi sensitivity. Therefore, we wanted to further examine HR-mediated repair through Rad51 loading onto DNA, which is a functional readout of HR (24) . PEO1-OR clones were irradiated (IR, 5Gy) and incubated for 4 hours. Cells were fixed and utilized for immunofluorescence against Rad51. IR-induced Rad51-positive cells were quantified for each PEO1-OR clone and we found a significant increase in IR-induced Rad51 positive cells in 3 of the 4 PEO1-OR clones compared to PEO1 parental cells (Sup. Fig. 3C-D) . Taken together, PARPi resistant cells have increased DNA damage repair capacity independent of BRCA2 reversion mutations, which correlates with increased Wnt/β-catenin signaling.
Obtaining primary tumors of recurrent PARPi resistant disease is difficult given the natural progression of treatment (2) . Therefore, we utilized a patient derived xenograft model (PDX) of a HGSOC primary tumor to recapitulate a recurrent tumor. Ascites containing malignant cells from a HGSOC patient were IP injected into nude SCID gamma mice and tumor bearing mice were treated with vehicle control or olaparib (50mg/kg daily). Following the cessation of olaparib, tumors were allowed to grow. After two months, ascites and tumor tissue were isolated from olaparib and control mice. RNA was extracted from ascites-derived tumor cells and FOSL1 expression was assessed as an indicator of Wnt activation. In two of the four olaparib treated mice there was a significant increase in FOSL1 expression compared to non-treated tumors suggesting a correlation between increased Wnt activation and olaparib insensitivity ( Fig. 5A ).
Utilizing an ex vivo model of a primary chemonaïve tumor we next examined the response of olaparib and/or Pyr. Pam. Primary tumors were sectioned with a Krumdieck tissue slicer, which produces uniform tissue slices that can be utilized for short-term culture. A HGSOC primary tumor was sectioned and tagged with a secreted luciferase (guassia luciferase; gLuc). gLuc activity has been utilized to measure proliferation and gLuc activity is directly correlated to cell proliferation (25) . GLuc-tagged tumor sections were treated with olaparib and/or Pyr. Pam..
Following 72 hours, media was refreshed, gLuc was allowed to accumulate for 4 hours and the amount of gLuc activity was measured ( Fig. 5B ). Olaparib and/or Pyr. Pam. treated tumor sections had significantly reduced gLuc activity compared to the vehicle control. Taken together these in vivo studies suggest that hyperactivation of Wnt leads to olaparib resistance and that Wnt inhibition alone or in combination are viable therapeutic approaches.
According to the American Cancer Society, 80% of all HGSOC are diagnosed at late stage indicating that tumor has disseminated to the peritoneal cavity (1) . Therefore, we wanted to examine the anti-tumor properties of combining olaparib with Pyr. Pam. in an intraperitoneal model of ovarian cancer. The in vitro results suggests an increase in Wnt signaling contributes to PARPi sensitivity and DNA damage repair therefore we wanted to recapitulate the WNT3Adependent PARPi resistance in vivo. Therefore, we injected luciferase/GFP-tagged PEO1-WNT3A expressing cells into the peritoneal cavity of immunocompromised mice. Tumors were allowed to establish for four weeks and were randomized based on luciferase activity and mouse weight. Mice were then treated daily for 21 days with vehicle control, olaparib, Pyr. Pam., or in combination. Measured by total flux (photons/sec), we observed that all treatments resulted in a significant reduction in tumor growth rate compared to control mice ( Fig. 5C and Sup. Fig. 4A ). Total tumor burden at the end of 21 days of treatment was measured and only the olaparib/Pyr. Pam. treated tumors resulted in a significant decrease in tumor weight compared to control (12.7 vs. 3.978mg, p=0.0365, Fig. 5D -E). Dissemination of tumors was measured by quantifying GFP-positive tumor nodules during necropsy. Only mice treated with Pyr. Pam. and olaparib/Pyr. Pam. demonstrated a significant reduction in total tumor nodules ( Fig. 5F) . With respect to toxicity, although not significant we did observe that mice in all of the treatment groups had reduced body weight (Sup. Fig. 4B ). The in vivo response observed in this xenograft model of HGSOC suggests that targeting Wnt signaling could prove to be an effective next-line therapeutic option following resistance to PARPi.
DISCUSSION:
Utilization of PARP inhibitors in the clinic is continuing to expand, which highlights an urgent need to better understand mechanisms of resistance. In this report, we established that HGSOC continually exposed to olaparib display hyperactivation of Wnt signaling and increased Transcriptome analysis of PEO1-OR cells revealed several significantly enriched signaling pathways and transcription factors, which highlights there are potentially multiple contributing pathways in promoting and maintaining PARPi resistance. We noted that PEO1 and OVCAR10 had an increase in TCF transcriptional activation, but OVSAHO cells did not have increased TCF activation. In the PEO1-OR TCF3 and LEF1 transcription factors were predicted to regulate a significant proportion of the olaparib resistant-related genes. Also, in a PDX model of recurrent olaparib insensitive tumors, a TCF target gene (FOSL1) was significantly upregulated. TCF/LEF transcriptional activation are highly dependent on Wnt/β-catenin activation. Therefore, we chose to further examine the relationship between Wnt signaling and PARPi response; however future work will evaluate the mechanism of olaparib resistance in OVSAHO cells. Wnt activation has been attributed to drive chemotherapy resistance in a variety of cancer types including prostate, colorectal, and ovarian (26) (27) (28) . Wnt signaling is a driver of several major biological processes including proliferation, stemness, epithelial-mesenchymal transition, and DNA damage.
Beyond TCF/LEF transcription factors, we noted in PEO1-OR cells that the heterodimeric AP-1 transcription factor was identified as a top transcriptional regulator of differentially expressed genes. There is significant crosstalk between Wnt signaling and AP-1 regulation. Wnt signaling mediated TCF activity directly promotes expression of AP-1 subunits (FOSL1, JUN). Notably, p53, BRCA, NFκB, and AP-1 play critical roles in promoting the expression of DNA repair genes such as ERCC4, ERCC6, and MGMT [Reviewed in (29) ]. BRCA-reversion mutations are the most well-described adaptation that leads to PARP inhibitor resistance (31, 32) . Transcript and protein analysis did not reveal secondary BRCA2 reversion events in PEO1-OR cells. Independent of BRCA-reversion mutations, replication fork stability has been shown to promote PARPi resistance; however we did not find that the hyperactivation of Wnt signaling induced a robust change in RF stability. We did observe that HR and distal NHEJ DNA damage repair were increased in PEO1-OR cells compared to sensitive and that mhNHEJ seemed to be less important. Distal NHEJ and mhNHEJ are predominantly performed by a similar set of effector proteins, but are distinguished by the DNA polymerases, DNA protein kinase (DNA-PK) and nucleases [Reviewed in (33) ], indicating that targeting the distal NHEJ pathway in PARPi resistant tumors is possible without inhibiting mhNHEJ.
In conclusion, hyperactivation of Wnt signaling contributes to and partially drives PARPi resistance independent of BRCA-reversion mutations. Inhibition of Wnt signaling reduces DNA repair capacity and significantly inhibits tumor progression in vivo. These findings offer a strong rationale to further examine the role of Wnt signaling in PARP inhibitor response.
MATERIALS AND METHODS:
Cell lines and culture conditions. Epithelial ovarian cancer (EOC) cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. 
Gynecologic Tissue and Fluid Bank (GTFB). The University of Colorado has an Institutional
Review Board approved protocol (COMIRB #07-935) in place to collect tissue from gynecologic patients with both malignant and benign disease processes. All participants are counseled regarding the potential uses of their tissue and sign a consent form approved by the Colorado Multiple Institutional Review Board. The tissues are processed, aliquoted, and stored at -80C.
Retrovirus and lentivirus transduction. Retrovirus production and transduction were performed as described previously (34) . Lentivirus was packaged using the Virapower Kit from Life Technologies (Carlsbad, CA) following the manufacturer's instructions as described previously (9) . shRNA and ORF were obtained from the Functional Genomics Facility at the University of Colorado. Cells transduced with virus encoding puromycin resistance gene were selected in 1 µg/ml puromycin. Table 1. Transcription factor enrichment in 1,819 PEO1-OR associated differentially regulated genes. Table 2 . KEGG pathway analysis from 1,819 PEO1-OR associated differentially regulated genes.
Reverse-transcriptase quantitative PCR (RT-qPCR). RNA was isolated from cells with the
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